<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211030052917N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-14</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Melatonin on sleep quality and cognitive function of hemodialysis patients</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Melatonin on Sleep Quality and Cognitive Function of Hemodialysis Patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>102</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/59703</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The present study is a randomized, double-blind clinical trial. The randomization method is through blocking. The randomization unit in this study is individual and the randomization tool is done through statistical software. Randomization will be done using Random allocation software. Samples are allocated in 17 blocks of six. That means 6 patients are placed in each block. Three patients are in the intervention group and the other three are in the control group, Blinding description: The present study is a randomized, double-blind clinical trial. All Dialysis patients participating in this study and the person distributing the drug They do not know which is Placebo to and which ones are Melatonin And only the supervising researcher knows about it. Participants in the present study are divided into two Groups. 
51 Participants will be in the Intervention Group and the next 51 will be in the Control Group. After selecting the Samples with inclusion Criteria, the blocking Method will be used for Random Allocation. After creating Random Numbers with the mentioned Software, the Blocking list is provided to the main Executor And the Samples will be entered into the Study accordingly. Patients in the intervention group will receive 3 mg of melatonin at night, half an hour before bedtime for 6 weeks. The packaging of placebo drugs is the same as melatonin in terms of shape, size, color and smell, and the way of receiving placebo will be the same as the intervention group.The results of both groups will be collected separately and compared at the end.</study_design>
      <phase>3</phase>
      <hc_freetext>The effect of melatonin on sleep quality and cognitive function in hemodialysis patients.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in the intervention Group will receive 3 mg of Melatonin (Razak Company, 3 mg per tablet) at Night, half an hour before bedtime for 6 Weeks. The questionnaire will be completed by the Patient herself or with the help of a Nurse at the beginning of the Study and after 6 weeks in the Group that received Melatonin. While obtaining the satisfaction of participating in the Study and emphasizing the use of drugs and the absence of side effects And by sending a short message to the Participants or a Member of the patient's family in this research, Patients are reminded about taking medicine. Intervention 2: Control group: Patients in the control group will receive a placebo for 6 weeks, half an hour before bedtime. The packaging of placebo drugs is the same as melatonin in terms of shape and size, and the way of receiving Placebo will be the same as the intervention Group. While obtaining the satisfaction of participating in the study and emphasizing the absence of Side effects And By sending a short message to the participants or a member of the patient's family in this study, Patients are reminded about taking Placebo.The placebo will be made by Razak company.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Marzie Salehi Hikoui</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dokhaniat Street, Etihad Alley, Vahdat Dead End, No. 30</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4813955641</zip>
        <telephone>+98 11 3323 6086</telephone>
        <email>marziesalehi12@gmai.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Hedayat Jafari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mazandaran, Sari, Amir Mazandarani St., Shahband St., Mehdiabad St., Nasibeh School of Nursing and Midwifery</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4816715793</zip>
        <telephone>+98 11 3336 7342</telephone>
        <email>hjafari@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>People 18 years and older
The patient should not involved in any other research project
The patient can give informed consent
Hemodialysis for more than 6 months
The patient has a Pittsburgh sleep quality index score higher than 5
The patient has a Montreal cognitive function index score lower than 26
The patient has adequate vision and hearing
The patient has normal thyroid tests</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The patient has already taken melatonin
The patient has a history of taking sleeping pills
The patient has a history of taking any drugs
The patient has an active infection
The patient is pregnant or breastfeeding
The patient has uncontrolled diabetes
The patient has dementia
The patient has liver disorders
The patient has cerebrovascular disorders
The patient needs  immediately Intervention for Hospitalization and surgery
The patient has heart failure
The patient has iron deficiency anemia
Patients taking anti-anxiety or hypnotic drugs due to neuropsychiatric disorders</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in the intervention Group will receive 3 mg of Melatonin (Razak Company, 3 mg per tablet) at Night, half an hour before bedtime for 6 Weeks. The questionnaire will be completed by the Patient herself or with the help of a Nurse at the beginning of the Study and after 6 weeks in the Group that received Melatonin. While obtaining the satisfaction of participating in the Study and emphasizing the use of drugs and the absence of side effects And by sending a short message to the Participants or a Member of the patient's family in this research, Patients are reminded about taking medicine.</i_keyword>
      <i_keyword>Control group: Patients in the control group will receive a placebo for 6 weeks, half an hour before bedtime. The packaging of placebo drugs is the same as melatonin in terms of shape and size, and the way of receiving Placebo will be the same as the intervention Group. While obtaining the satisfaction of participating in the study and emphasizing the absence of Side effects And By sending a short message to the participants or a member of the patient's family in this study, Patients are reminded about taking Placebo.The placebo will be made by Razak company.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Patients' sleep quality Score on the Pittsburgh Sleep Quality Assessment Tool. Timepoint: Measurement of Sleep Quality at the beginning of the Study (before the intervention) and immediately after the intervention in the intervention Group and Control Group. Method of measurement: Pittsburgh Sleep Quality Questionnaire.</prim_outcome>
      <prim_outcome>Patients' cognitive Function score in the Montreal Cognitive Assessment Tool. Timepoint: Measurement of cognitive Functions at the beginning of the Study (before the intervention) and immediately after the intervention in the intervention Group and Control Group. Method of measurement: Montreal Cognitive Assessment Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-26</approval_date>
        <contact_name>Ethic committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Mazandaran, Sari, Amir Mazandarani St., Shahband St., Mehdiabad St., Nasibeh School of Nursing and Midwifery Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
